Avibactam/ceftazidime

Drug Profile

Avibactam/ceftazidime

Alternative Names: AVE 1330/ceftazidime; AVE 1330A/ceftazidime; Avibactam/ceftazidime pentahydrate; AVYCAZ; CAZ 104; CAZ-AVI; Ceftazidime pentahydrate/avibactam; Ceftazidime/AVE 1330; Ceftazidime/AVE 1330A; Ceftazidime/NXL 104; NXL 104/ceftazidime; Zavicefta

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novexel
  • Developer Allergan; AstraZeneca; Cerexa; Novexel; Pfizer
  • Class Amides; Cephalosporins; Heterocyclic bicyclo compounds; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections

Most Recent Events

  • 14 Mar 2017 Launched for Gram-negative infections, Nosocomial pneumonia, Urinary tract infections and Intra-abdominal infections (Combination therapy) in Germany, United Kingdom (IV)
  • 30 Jan 2017 US FDA approves sNDA for avibactam/ceftazidime to update the label with new phase III trial results for Urinary tract infections in January 2017
  • 12 Oct 2016 US FDA accepts sNDA to review for avibactam/ceftazidime to update the label with new phase III trial results for Urinary tract infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top